JPMorgan Chase & Co. Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its price objective raised by JPMorgan Chase & Co. from $152.00 to $170.00 in a report issued on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 8.89% from the company’s current price.

Several other research firms also recently commented on PODD. UBS Group reduced their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating on the stock in a report on Thursday, August 6th. Wells Fargo & Company raised their price objective on Insulet from $144.00 to $172.00 and gave the stock an “equal weight” rating in a research report on Thursday. Sanford C. Bernstein boosted their price target on Insulet from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday. Jefferies Financial Group reiterated a “buy” rating and issued a $200.00 price objective on shares of Insulet in a research note on Wednesday. Finally, Barclays raised Insulet to a “hold” rating in a report on Wednesday, October 7th. Thirteen research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $191.52.

Insulet Trading Down 5.4%

PODD stock traded down $8.90 during midday trading on Thursday, reaching $156.12. 1,319,217 shares of the company traded hands, compared to its average volume of 1,397,991. The business has a 50 day moving average of $141.65 and a 200-day moving average of $178.00. Insulet has a 52-week low of $126.40 and a 52-week high of $354.88. The firm has a market capitalization of $10.83 billion, a price-to-earnings ratio of 29.18, a P/E/G ratio of 1.22 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40. The business had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business’s revenue was up 19.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.24 earnings per share. As a group, sell-side analysts expect that Insulet will post 6.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Insulet

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in shares of Insulet in the second quarter worth about $1,018,582,000. Arrowstreet Capital Limited Partnership grew its stake in Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after acquiring an additional 1,011,369 shares in the last quarter. Amundi grew its stake in Insulet by 14.4% during the 1st quarter. Amundi now owns 446,918 shares of the medical instruments supplier’s stock valued at $93,781,000 after acquiring an additional 56,225 shares in the last quarter. Renaissance Technologies LLC grew its stake in Insulet by 40.5% during the 1st quarter. Renaissance Technologies LLC now owns 426,003 shares of the medical instruments supplier’s stock valued at $89,392,000 after acquiring an additional 122,720 shares in the last quarter. Finally, Man Group plc acquired a new stake in Insulet in the 2nd quarter valued at about $78,746,000.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 earnings of $1.99 per share, topping the $1.59 consensus, while revenue rose 19.2% year over year to $842 million and also beat estimates. The company raised its 2026 outlook and announced a $1 billion share-repurchase program. Insulet CEO Sees Slower Growth in 2027
• Positive Sentiment: Several analysts raised price targets after the results. RBC lifted its target to $180 and retained an Outperform rating; Bernstein raised its target to $200 and also rated the stock Outperform. RBC Raises Price Target
• Neutral Sentiment: Other firms also increased targets, including Citi to $170, Leerink Partners to $167, Wells Fargo to $172 and UBS to $171, but kept Neutral, Market Perform or Equal Weight ratings. RBC sees an attractive valuation, while noting a more conservative 2027 outlook. Insulet Sees Attractive Valuation
• Negative Sentiment: Management expects slower growth in 2027 and anticipates rivals will take some share from its Omnipod product. That forward-looking caution appears to be weighing on the stock despite the strong quarter. Insulet CEO Sees Slower Growth in 2027

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.